Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF)

Professor Gregory Lip; José Luís Merino; Maciej Banach; Joris R. de Groot; Lars S. Maier; Sakis Themistoclakis; Giuseppe Boriani; James Jin; Michael Melino; Shannon M. Winters; Andreas Goette

doi:10.1016/j.amjcard.2018.11.019

Shared by

Professor Gregory Lip

University of Liverpool

Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF)

Article 2018 en

Authors

Professor Gregory Lip
University of Liverpool
JM
José Luís Merino
MB
Maciej Banach

Related publications

Article2017

Abstract 18190: Impact of Age and Gender on Clinical Outcomes in the Edoxaban versus Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation (ENSURE-AF) Randomized Trial

Andreas Goette, Joris R. de Groot, Jean‐Yves Le Heuzey, Maciej Banach, Kurt Huber, James Jin, Michael Melino, Shannon M. Winters, Sakis Themistoclakis, Professor Gregory Lip

Article2016

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Andreas Goette, José Luís Merino, Michael D. Ezekowitz, Dmitry Zamoryakhin, Michael Melino, James Jin, Michele Mercuri, Michael Grosso, Víctor Fernández, Naab Al‐Saady, Natalya Pelekh, Béla Merkely, Sergey Zenin, Mykola Kushnir, Jindřich Špinar, Valeriy Batushkin, Joris R. de Groot, Professor Gregory Lip

Article2018

P1003Effect of concomitant antiplatelet agents on clinical outcomes in the Edoxaban versus Warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial

Andreas Goette, José Luís Merino, Raffaele De Caterina, Kurt Huber, Hein Heidbüchel, James Jin, Michael Melino, Shannon M. Winters, Professor Gregory Lip

Article2020

Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE‐AF) randomized trial

Professor Gregory Lip, José Luís Merino, Maciej Banach, Naab Al‐Saady, James Jin, Michael Melino, Shannon M. Winters, Monika Kozieł, Andreas Goette

Article2020

Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial

Andreas Goette, José Luís Merino, Raffaele De Caterina, Kurt Huber, Hein Heidbüchel, James Jin, Professor Gregory Lip

Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF)

Discussion(0)

Related publications

Abstract 18190: Impact of Age and Gender on Clinical Outcomes in the Edoxaban versus Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation (ENSURE-AF) Randomized Trial

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

P1003Effect of concomitant antiplatelet agents on clinical outcomes in the Edoxaban versus Warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial

Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE‐AF) randomized trial

Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial